BREO Drug Patent Profile
✉ Email this page to a colleague
When do Breo patents expire, and what generic alternatives are available?
Breo is a drug marketed by Glaxo Grp Ltd and is included in one NDA. There are four patents protecting this drug.
The generic ingredient in BREO is fluticasone furoate; vilanterol trifenatate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate; vilanterol trifenatate profile page.
DrugPatentWatch® Generic Entry Outlook for Breo
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BREO?
- What are the global sales for BREO?
- What is Average Wholesale Price for BREO?
Summary for BREO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for BREO |
| Drug Sales Revenues: | Drug sales revenues for BREO |
| DailyMed Link: | BREO at DailyMed |
US Patents and Regulatory Information for BREO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-003 | May 12, 2023 | RX | Yes | Yes | 8,511,304*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | 8,746,242*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-003 | May 12, 2023 | RX | Yes | Yes | 11,116,721*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
